X-COR Therapeutics is a Boston based medical device company creating the first commercially available CO2 removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR was the runner-up in the 2018 Harvard President’s Innovation Challenge with the ACORN device, a novel consumable hybrid cartridge that removes CO2 from patients’ blood with less invasive procedures than high-flow alternatives. X-COR is part of the 2018 MedTech Innovator and MassChallenge cohorts.
The ACORN is a patent-pending medical device that allows physicians to remove excess CO2 from patients who are in symptomatic lung failure. ACORN is compatible with existing medical device infrastructure for ease of use and deployment. Unlike other technologies to treat lung failure, ACORN uses a hybrid approach that allows patients’ blood to be drawn at <300 ml/min flows through small catheters that can be placed by nursing staff. This therapy is more affordable, safer, and more accessible than existing comparable extracorporeal devices that often require >3 L/min flows and highly specialized physicians.